June 4, 2018

BUHLMANN Laboratories AG   
Roshana Ahmed   
Associate Director, Regulatory Affairs   
Mapi SRS, an ICON plc Company   
2343 Alexandria Drive   
Suite 100   
Lexington, Kentucky 40504

Re: K181012 Trade/Device Name: BUHLMANN fCAL ELISA Regulation Number: 21 CFR 866.5180 Regulation Name: Fecal calprotectin immunological test system Regulatory Class: Class II Product Code: NXO Dated: April 16, 2018 Received: April 17, 2018

Dear Roshana Ahmed:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).   
For   
Lea Carrington, Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

![](images/d3db7ca316da706c9a6d5f914a05828a9ce27fe0da86929291a01b974a4c8632.jpg)

Enclosure

Indications for Use (Describe)

The BÜHLMANN fCAL $^ \mathrm { \textregistered }$ ELISA is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL $^ { \mathrm { \textregistered } }$ ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# 510(k) Summary

# I. Submitter

BÜHLMANN Laboratories AG   
Baselstrasse 55   
Schönenbuch CH-4124   
Switzerland   
Phone: $+ 4 1$ 61 487 12 44

Contact Person: Alicja Ritz, Ph.D., Head Regulatory Affairs Date Prepared: May 22, 2018

# II. Device

<table><tr><td rowspan=1 colspan=1>Device Proprietary Name:</td><td rowspan=1 colspan=1>BUHLMANN fCAL® ELISA</td></tr><tr><td rowspan=1 colspan=1>Common or Usual Name:</td><td rowspan=1 colspan=1>Fecal calprotectin immunological test system</td></tr><tr><td rowspan=1 colspan=1>Classification Name:</td><td rowspan=1 colspan=1>Calprotectin, Fecal</td></tr><tr><td rowspan=1 colspan=1>Regulation Number:</td><td rowspan=1 colspan=1>21 CFR 866.5180</td></tr><tr><td rowspan=1 colspan=1>Product Code:</td><td rowspan=1 colspan=1>NXO</td></tr><tr><td rowspan=1 colspan=1>Device Classification</td><td rowspan=1 colspan=1>I</td></tr></table>

# III. Predicate Device

Substantial equivalence is claimed to the following device:

• Calprest®NG, K160447, Eurospital S.p.A.

# IV. Device Description

The BÜHLMANN fCAL® ELISA is an enzyme-linked immunosorbent assay (ELISA) performed using patient stool extracts collected without preservatives. Calprotectin within the extract binds to protein specific antibodies coated on the well surface. An enzyme conjugated antibody detects the captured antigen. Incubation of the complex with substrate results in a colored product which reflects the amount of calprotectin in the sample. Quantification of calprotectin concentration is achieved using standard plate readers.

# V. Indications for Use

The BÜHLMANN fCAL® ELISA is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

# VI. Comparison of Technological Characteristics

The BÜHLMANN fCAL® ELISA and the Calprest $^ { \mathrm { \textregistered } } _ { \mathrm { N G } }$ share the following characteristics:

• use of ELISA technology to detect calprotectin in stool samples; use of quantitative assay format; use of 96 well microtiter plate; use of TMB as substrate; and optical density reading at $4 5 0 \mathrm { n m }$ .

The BÜHLMANN fCAL® ELISA is technologically different from the Calprest®NG as follows:

use of different sample extraction buffers and sample dilution;   
• use of different antibodies for microtiter plate coating; use of different detection antibodies;   
• use of different calibrator concentrations; use of a different standardization; different clinical thresholds; and different reportable ranges.

The tables below compares key technological features between the subject and predicate devices.

# Technological comparison

# BÜHLMANN fCAL® ELISA Reagents

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>BÜHLMANN fCAL® ELISA</td><td rowspan=1 colspan=1>Calprest®NG(K160447)</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Colorimetric ELISA</td><td rowspan=1 colspan=1>Colorimetric ELISA</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Calprotectin</td><td rowspan=1 colspan=1>Calprotectin</td></tr><tr><td rowspan=1 colspan=1>Assay Format</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Quantitative</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Fecal</td><td rowspan=1 colspan=1>Fecal</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>96-well microtiter plate</td><td rowspan=1 colspan=1>96-well microtiter plate</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>HRP Horse Radish Peroxidase</td><td rowspan=1 colspan=1>HRP Horse Radish Peroxidase</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>TMB</td></tr><tr><td rowspan=1 colspan=1>OD Reading</td><td rowspan=1 colspan=1>450 nm</td><td rowspan=1 colspan=1>450 nm</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>BÜHLMANN fCAL¥ ELISA</td><td rowspan=1 colspan=1>Calprest®NG(K160447)</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>30 - 1800 μg/g (mg/kg)</td><td rowspan=1 colspan=1>27.1 - 3000 mg/kg</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>&lt;1g</td><td rowspan=1 colspan=1>1-5g</td></tr><tr><td rowspan=1 colspan=1>Sample Dilution</td><td rowspan=1 colspan=1>1:7500</td><td rowspan=1 colspan=1>1:20,000</td></tr><tr><td rowspan=1 colspan=1>Result interpretation</td><td rowspan=1 colspan=1>Normal: &lt; 80 μg/gGray-zone: 80 - 160 μg/gElevated: &gt; 160 μg/g</td><td rowspan=1 colspan=1>Normal: &lt; 50 mg/kg (μg/g)Borderline: 50 - 120 mg/kg(μg/g)Abnormal: &gt; 120 mg/kg (μg/g)</td></tr></table>

# BÜHLMANN fCAL® ELISA Controls

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>BÜHLMANN fCAL® ELISA</td><td rowspan=1 colspan=1>Calprest®NG(K160447)</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>BUHLMANN fCAL® ELISA</td><td rowspan=1 colspan=1>Calprest®NG</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Native human calprotectin</td><td rowspan=1 colspan=1>Recombinant calprotectin antigen(rAg)</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>2 (high and low)</td><td rowspan=1 colspan=1>2 (high and low)</td></tr><tr><td rowspan=1 colspan=1>Physio-chemicalcharacteristics</td><td rowspan=1 colspan=1>Ready to use</td><td rowspan=1 colspan=1>Ready to use</td></tr></table>

# BÜHLMANN fCAL® ELISA Calibrators

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>BÜHLMANN fCAL® ELISA</td><td rowspan=1 colspan=1>Calprest®NG(K160447)</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>BÜHLMANN fCAL® ELISA</td><td rowspan=1 colspan=1>Calprest®NG</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Native human calprotectin</td><td rowspan=1 colspan=1>Recombinant calprotectin antigen(rAg)</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>5 levels:4, 12, 40, 120, and 240 ng/mL</td><td rowspan=1 colspan=1>6 levels:0, 2.5, 12.5, 25, 50, and 150ng/mL</td></tr><tr><td rowspan=1 colspan=1>Conversion factor</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Nominal ValueAssignment</td><td rowspan=1 colspan=1>30 μg/g90 μg/g300 μg/g900 μg/g1800 μg/g</td><td rowspan=1 colspan=1>050 μg/g250 μg/g500 μg/g1000 μg/g3000 μg/g</td></tr></table>

# Discussion

As seen above, the differences between the subject and predicate devices include the use of different sample extraction buffers and dilution ratios, use of different antibodies and calibrator concentrations, and use of different cut-offs. These differences are addressed by the performance data identified below.

# VII. Summary of Performance Characteristics

The following performance studies were conducted in support of the substantial equivalence determination:

• establishment of clinical thresholds;   
• traceability/standardization;   
• precision/reproducibility;   
• linearity; accuracy/recovery;   
• interfering substances;   
• analytical sensitivity;   
• stability (analyte and reagent); and clinical study.

# A. Clinical Thresholds

<table><tr><td rowspan=1 colspan=1>Calprotectin Concentration</td><td rowspan=1 colspan=1>Interpretation</td><td rowspan=1 colspan=1>Follow-Up</td></tr><tr><td rowspan=1 colspan=1>&lt; 80 μg/g</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>None</td></tr><tr><td rowspan=1 colspan=1>80 μg/g ≤ x ≤ 160 μg/g</td><td rowspan=1 colspan=1>Gray-zone/Borderline</td><td rowspan=1 colspan=1>Retest within 4 - 6 weeks</td></tr><tr><td rowspan=1 colspan=1>&gt; 160 μg/g</td><td rowspan=1 colspan=1>Elevated</td><td rowspan=1 colspan=1>Retest as appropriate</td></tr></table>

# B. Precision

Single-Site Repeatability Study Results

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Within-run(Repeatability)</td><td rowspan=1 colspan=2>Between-run</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Total(Within-Laboratory)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>P1</td><td rowspan=1 colspan=1>38.5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>9.4%</td></tr><tr><td rowspan=1 colspan=1>P2</td><td rowspan=1 colspan=1>67.0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>6.4%</td></tr><tr><td rowspan=1 colspan=1>P3</td><td rowspan=1 colspan=1>135.7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>4.4%</td></tr><tr><td rowspan=1 colspan=1>P4</td><td rowspan=1 colspan=1>207.1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>6.4%</td></tr><tr><td rowspan=1 colspan=1>P5</td><td rowspan=1 colspan=1>337.1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>19.3</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>P6</td><td rowspan=1 colspan=1>562.6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>17.7</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td rowspan=1 colspan=1>P7</td><td rowspan=1 colspan=1>918.0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>18.6</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>62.1</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>20.8</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>68.1</td><td rowspan=1 colspan=1>7.4%</td></tr></table>

-This space intentionally left blank--

Multi-Site Precision Study Results   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Between-run</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Between-operator</td><td rowspan=1 colspan=2>Between-site</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>S01</td><td rowspan=1 colspan=1>41.4</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>19.6%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>9.9%</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>23.2%</td></tr><tr><td rowspan=1 colspan=1>S02</td><td rowspan=1 colspan=1>67.2</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>10.4%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>13.0%</td></tr><tr><td rowspan=1 colspan=1>S03</td><td rowspan=1 colspan=1>143.0</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>12.1%</td></tr><tr><td rowspan=1 colspan=1>S04</td><td rowspan=1 colspan=1>379.8</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>16.4</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>13.7</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>24.2</td><td rowspan=1 colspan=1>6.4%</td></tr><tr><td rowspan=1 colspan=1>S05</td><td rowspan=1 colspan=1>1056.6</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>40.1</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>53.8</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>39.6</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>67.6</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>103.1</td><td rowspan=1 colspan=1>9.8%</td></tr></table>

Lot-to-Lot Reproducibility Study Results   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(μg/g)</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Between-reader</td><td rowspan=1 colspan=2>Between-operator</td><td rowspan=1 colspan=2>Between-lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>46.4</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>9.7%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>105.5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>4.2%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>133.6</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>5.4%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>178.5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>435.2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>18.1</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>23.2</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1476.1</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>48.4</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>88.6</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>32.2</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>31.4</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>110.6</td><td rowspan=1 colspan=1>7.5%</td></tr></table>

# Extraction Reproducibility Study Results

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(μg/g)</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Within-extraction</td><td rowspan=1 colspan=2>Between-extraction</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(μg/g)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>S01</td><td rowspan=1 colspan=1>51.2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>8.9%</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>15.2%</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>17.6%</td></tr><tr><td rowspan=1 colspan=1>S03</td><td rowspan=1 colspan=1>88.3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>15.0%</td><td rowspan=1 colspan=1>14.8</td><td rowspan=1 colspan=1>16.8%</td></tr><tr><td rowspan=1 colspan=1>S05</td><td rowspan=1 colspan=1>66.8</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>15.8%</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>16.7%</td></tr><tr><td rowspan=1 colspan=1>S06</td><td rowspan=1 colspan=1>179.3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>16.8</td><td rowspan=1 colspan=1>9.4%</td><td rowspan=1 colspan=1>32.8</td><td rowspan=1 colspan=1>18.3%</td><td rowspan=1 colspan=1>36.8</td><td rowspan=1 colspan=1>20.5%</td></tr><tr><td rowspan=1 colspan=1>S07</td><td rowspan=1 colspan=1>366.1</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>22.4</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>32.3</td><td rowspan=1 colspan=1>8.8%</td><td rowspan=1 colspan=1>39.3</td><td rowspan=1 colspan=1>10.7%</td></tr><tr><td rowspan=1 colspan=1>S08</td><td rowspan=1 colspan=1>327.4</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>15.4</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>26.9</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>31.0</td><td rowspan=1 colspan=1>9.5%</td></tr><tr><td rowspan=1 colspan=1>S09</td><td rowspan=1 colspan=1>1783.7</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>198.3</td><td rowspan=1 colspan=1>11.1%</td><td rowspan=1 colspan=1>262.0</td><td rowspan=1 colspan=1>14.7%</td><td rowspan=1 colspan=1>328.6</td><td rowspan=1 colspan=1>18.4%</td></tr></table>

# C. Linearity

Analytical measuring range: $3 0 - 1 8 0 0 ~ \mu \mathrm { g / g }$ .

# D. Accuracy/Recovery

<table><tr><td rowspan=1 colspan=1>SpecimenExtract</td><td rowspan=1 colspan=1>Mean BaselineResult (μg/g)</td><td rowspan=1 colspan=1>Expected Post-Spike Result (μg/g)</td><td rowspan=1 colspan=1>Observed Post-SpikeResult (μg/g)</td><td rowspan=1 colspan=1>Recoveryrate (%)</td></tr><tr><td rowspan=1 colspan=1>#1</td><td rowspan=1 colspan=1>46.5</td><td rowspan=1 colspan=1>226.5</td><td rowspan=1 colspan=1>224.5</td><td rowspan=1 colspan=1>99.1%</td></tr><tr><td rowspan=1 colspan=1>#2</td><td rowspan=1 colspan=1>63.7</td><td rowspan=1 colspan=1>243.7</td><td rowspan=1 colspan=1>247.7</td><td rowspan=1 colspan=1>101.6%</td></tr><tr><td rowspan=1 colspan=1>#3</td><td rowspan=1 colspan=1>89.0</td><td rowspan=1 colspan=1>269.0</td><td rowspan=1 colspan=1>274.9</td><td rowspan=1 colspan=1>102.2%</td></tr><tr><td rowspan=1 colspan=1>#4</td><td rowspan=1 colspan=1>111.6</td><td rowspan=1 colspan=1>291.6</td><td rowspan=1 colspan=1>292.0</td><td rowspan=1 colspan=1>100.1%</td></tr><tr><td rowspan=1 colspan=1>#5</td><td rowspan=1 colspan=1>163.5</td><td rowspan=1 colspan=1>343.5</td><td rowspan=1 colspan=1>331.1</td><td rowspan=1 colspan=1>96.4%</td></tr><tr><td rowspan=1 colspan=1>#6</td><td rowspan=1 colspan=1>304.0</td><td rowspan=1 colspan=1>484.0</td><td rowspan=1 colspan=1>475.0</td><td rowspan=1 colspan=1>98.1%</td></tr><tr><td rowspan=1 colspan=1>#7</td><td rowspan=1 colspan=1>990.2</td><td rowspan=1 colspan=1>1170.2</td><td rowspan=1 colspan=1>1166.6</td><td rowspan=1 colspan=1>99.7%</td></tr></table>

# E. Analytical Sensitivity

$\mathrm { L o B } = 8 . 3 ~ \mathrm { \mu g / g \ ( m g / k g ) }$ $\mathrm { L o D } = 1 2 . 6 ~ \mathrm { \mu g / g ~ ( m g / k g ) }$ $\mathrm { L o Q } = 3 0 ~ \mu \mathrm { g / g } \left( \mathrm { m g / k g } \right)$

# $F$ . Interfering Substances

Study procedures were performed using the following four (4) stool specimen extracts:

• one extract with calprotectin concentration close to the lower measuring limit of 30 $\mu \mathrm { g } / \mathrm { g } ;$ ; • one extract with calprotectin concentration of approximately $1 0 0 ~ \mu \mathrm { g / g }$ ; • one extract with calprotectin concentration of approximately $2 0 0 \mu \mathrm { g } / \mathrm { g } ;$ and • one extract with calprotectin concentration of approximately $5 0 0 ~ \mu \varrho / \varrho$ .

The following analytes, pharmaceuticals and nutritional supplements did not interfere with the BÜHLMANN fCAL® ELISA when added to stool extracts at the given test concentrations:

<table><tr><td rowspan=1 colspan=1>Trade name</td><td rowspan=1 colspan=1>Active component</td><td rowspan=1 colspan=1>Solvent</td><td rowspan=1 colspan=1>Concentration(mg/mL)</td></tr><tr><td rowspan=1 colspan=1>gyno-Tardyferon</td><td rowspan=1 colspan=1>Iron (II) sulfate</td><td rowspan=1 colspan=1>HC1 / NaOH</td><td rowspan=1 colspan=1>0.04</td></tr><tr><td rowspan=1 colspan=1>Prednisone</td><td rowspan=1 colspan=1>Prednisone</td><td rowspan=1 colspan=1>DMSO</td><td rowspan=1 colspan=1>0.13</td></tr><tr><td rowspan=1 colspan=1>Imurek</td><td rowspan=1 colspan=1>Azathioprine</td><td rowspan=1 colspan=1>DMSO</td><td rowspan=1 colspan=1>0.08</td></tr><tr><td rowspan=1 colspan=1>Salofalk</td><td rowspan=1 colspan=1>Mesalamine; 5-ASA</td><td rowspan=1 colspan=1>DMSO</td><td rowspan=1 colspan=1>2.09</td></tr><tr><td rowspan=1 colspan=1>Agopton</td><td rowspan=1 colspan=1>Lansoprazole</td><td rowspan=1 colspan=1>Dimethylformamide</td><td rowspan=1 colspan=1>0.07</td></tr><tr><td rowspan=1 colspan=1>Asacol</td><td rowspan=1 colspan=1>Mesalamine; 5-ASA</td><td rowspan=1 colspan=1>DMSO</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Vancocin</td><td rowspan=1 colspan=1>Vancomycin</td><td rowspan=1 colspan=1>HOdd</td><td rowspan=1 colspan=1>0.80</td></tr><tr><td rowspan=1 colspan=1>Sulfamethoxazole</td><td rowspan=1 colspan=1>Sulfamethoxazole</td><td rowspan=1 colspan=1>DMSO</td><td rowspan=1 colspan=1>0.64</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim</td><td rowspan=1 colspan=1>Trimethoprim lactate</td><td rowspan=1 colspan=1>DMSO / Exbuffer</td><td rowspan=1 colspan=1>0.14</td></tr><tr><td rowspan=1 colspan=1>Ciproxine</td><td rowspan=1 colspan=1>Ciprofloxacin</td><td rowspan=1 colspan=1>solvent from manufacturer /H2Odd</td><td rowspan=1 colspan=1>0.50</td></tr><tr><td rowspan=1 colspan=1>Vitamin E</td><td rowspan=1 colspan=1>DL-α Tocopherol Acetate</td><td rowspan=1 colspan=1>H2O+Tween</td><td rowspan=1 colspan=1>0.12</td></tr><tr><td rowspan=1 colspan=1>Bion 3</td><td rowspan=1 colspan=1>Multivitamin</td><td rowspan=1 colspan=1>HCl / NaOH</td><td rowspan=1 colspan=1>0.43</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>H2Odd</td><td rowspan=1 colspan=1>0.50</td></tr></table>

The following microorganisms did not interfere with the BÜHLMANN fCAL® ELISA when added to stool extracts at the given cell counts:

G. Clinical Study (Clinical Sensitivity/Specificity of IBD vs. non-IBD)   

<table><tr><td rowspan=1 colspan=1>Microorganism</td><td rowspan=1 colspan=1>Concentration(cfu/mL)</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=1>9.5 x 107</td></tr><tr><td rowspan=1 colspan=1>Salmonella enterica subsp. enterica</td><td rowspan=1 colspan=1>1 x 109</td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae subsp. pneumonia</td><td rowspan=1 colspan=1>5.4 x 107</td></tr><tr><td rowspan=1 colspan=1>Citrobacter freundii</td><td rowspan=1 colspan=1>9.7 x 107</td></tr><tr><td rowspan=1 colspan=1>Shigella flexneri</td><td rowspan=1 colspan=1>1.5 x 108</td></tr><tr><td rowspan=1 colspan=1>Yersinia enterocolitica subsp. enterocolitica</td><td rowspan=1 colspan=1>1.6 x 108</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Borderline Valuesconsidered Positive</td><td rowspan=1 colspan=2>IBD</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>BUHLMANNfCALELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>186</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>151</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>202</td><td rowspan=1 colspan=1>337</td></tr><tr><td rowspan=1 colspan=5>Sensitivity = 93.3%; 95% C.I. (87.7%, 96.9%)</td></tr><tr><td rowspan=1 colspan=5>Specificity = 70.3%; 95% C.I. (63.5%, 76.5%)</td></tr><tr><td rowspan=1 colspan=5>PPV = 67.7%; 95% C.I. (60.5%, 74.4%)</td></tr><tr><td rowspan=1 colspan=5>NPV = 94.0%; 95% C.I. (89.0%, 97.2%)</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Borderline Valuesconsidered Negative</td><td rowspan=1 colspan=2>IBD</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>BUHLMANNfCALELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>147</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>190</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>202</td><td rowspan=1 colspan=1>337</td></tr><tr><td rowspan=1 colspan=5>Sensitivity = 84.4%; 95% C.I. (77.2%, 90.1%)</td></tr><tr><td rowspan=1 colspan=5>Specificity = 83.7%; 95% C.I. (77.8%, 88.5%)</td></tr><tr><td rowspan=1 colspan=5>PPV = 77.6%; 95% C.I. (69.9%, 84.0%)</td></tr><tr><td rowspan=1 colspan=5>NPV = 88.9%; 95% C.I. (83.6%, 93.0%)</td></tr></table>

H. Clinical Study (Clinical Sensitivity/Specificity of IBD vs. IBS)   

<table><tr><td rowspan=2 colspan=2>Borderline Valuesconsidered Positive</td><td rowspan=1 colspan=2>Clinical Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>IBD</td><td rowspan=1 colspan=1>IBS</td></tr><tr><td rowspan=3 colspan=1>BUHLMANNfCALELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>162</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>265</td></tr><tr><td rowspan=1 colspan=5>Sensitivity = 93.3%; 95% C.I. (87.7%, 96.9%)</td></tr><tr><td rowspan=1 colspan=5>Specificity = 72.3%; 95% C.I. (63.8%, 79.8%)</td></tr><tr><td rowspan=1 colspan=5>PPV = 77.8%; 95% C.I. (70.6%, 83.9%)</td></tr><tr><td rowspan=1 colspan=5>NPV = 91.3%; 95% C.I. (84.1%, 95.9%)</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Borderline Valuesconsidered Negative</td><td rowspan=1 colspan=2>Clinical Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>IBD</td><td rowspan=1 colspan=1>IBS</td></tr><tr><td rowspan=3 colspan=1>BUHLMANNfCALELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>133</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>132</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>265</td></tr><tr><td rowspan=1 colspan=5>Sensitivity = 84.4%; 95% C.I. (77.2%, 90.1%)</td></tr><tr><td rowspan=1 colspan=5>Specificity = 85.4%; 95% C.I. (78.1%, 91.0%)</td></tr><tr><td rowspan=1 colspan=5>PPV = 85.7%; 95% C.I. (78.6%, 91.2%)</td></tr><tr><td rowspan=1 colspan=5>NPV = 84.1%; 95% C.I. (76.7%, 89.9%)</td></tr></table>

# VIII. Conclusion

The information provided above supports that the BÜHLMANN fCAL® ELISA is as safe and effective as the predicate devices. Although technological differences exist between the subject and predicate devices, performance testing supports that these differences do not raise any new questions of safety and effectiveness. Therefore, it is concluded that the BÜHLMANN fCAL® ELISA is substantially equivalent to the predicate devices.